---
title: "Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from CICC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280746908.md"
description: "CICC analyst has maintained a Buy rating on Wuxi Biologics (Cayman) with a price target of HK$48.00, while the shares closed at HK$31.54. The analyst consensus is Strong Buy, with a target of HK$45.23, indicating a 43.41% upside. CMB International Securities also supports a Buy rating with a target of HK$39.00."
datetime: "2026-03-27T07:36:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280746908.md)
  - [en](https://longbridge.com/en/news/280746908.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280746908.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280746908.md) | [繁體中文](https://longbridge.com/zh-HK/news/280746908.md)


# Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from CICC

CICC analyst maintained a Buy rating on Wuxi Biologics (Cayman) yesterday and set a price target of HK$48.00. The company’s shares closed last Wednesday at HK$31.54.

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Wuxi Biologics (Cayman) has an analyst consensus of Strong Buy, with a price target consensus of HK$45.23, a 43.41% upside from current levels. In a report released yesterday, CMB International Securities also maintained a Buy rating on the stock with a HK$39.00 price target.

### Related Stocks

- [WUXI BIO POFF-D (44048.HK)](https://longbridge.com/en/quote/44048.HK.md)
- [WUXI BIO (02269.HK)](https://longbridge.com/en/quote/02269.HK.md)
- [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/en/quote/513700.CN.md)
- [WuXi Biologics (Cayman) Inc. (WXXWY.US)](https://longbridge.com/en/quote/WXXWY.US.md)

## Related News & Research

- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/en/news/281054154.md)
- [ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma](https://longbridge.com/en/news/281068292.md)
- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/en/news/280923090.md)
- [WuXi Biologics Shareholder to Sell Shares](https://longbridge.com/en/news/272769159.md)
- [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/en/news/281103720.md)